For decades, regulators have had only limited success in taming a for-profit college industry that routinely defrauds students, inflates prices, and produces devastatingly bad outcomes for student loan borrowers. But recently, instead of promoting complex regulatory schemes, some policymakers have offered a simple solution: take away for-profit colleges’ federal subsidies. Today, Rep. Pramila Jayapal (D-WA)

Corporate profits and executive pay are sky high today, while wages for most American workers have remained low and stagnant over the past several decades. Today’s high-profit, low-wage economy is, in part, a result of rules and policies that shape corporate decision-making. These rules have allowed CEOs, shareholders, and executives to move more and more

Late last month, the Business Roundtable (BRT)—a collection of 181 of the country’s largest corporations—announced that it was breaking from over 20 years of precedent. Instead of prioritizing shareholder value over everything else, the BRT declared that it would elevate the interests of all other stakeholders—including customers, communities, and suppliers—alongside it. Most notably, the very

In a working paper, Roosevelt Senior Economist and Policy Counsel Lenore Palladino investigates whether stock buybacks occur more frequently, independent of other factors, when corporate insiders are selling their own personal shareholdings. In her empirical analysis of the relationship between insider sales and stock buybacks, Palladino finds that a 10 percent increase in insider sales

FOR IMMEDIATE RELEASE: June 19, 2019 CONTACT: Ariela Weinberger, aweinberger@rooseveltinstitute.org The High Cost of Shareholder Power in Big Pharma New Roosevelt brief illustrates the magnitude of Big Pharma spending on shareholders NEW YORK, NY – At a time when Americans pay record prices for medications, pharmaceutical companies generate record profits devoted largely to rewarding shareholders

Despite Big Pharma’s claim that high-cost medicines are the price society must pay for innovation, recent research provides ample evidence that overpriced medicines are not necessary for the industry to find cures or revolutionize. Rather, high-cost and low-quality medicines are the price patients pay for an industry that prioritizes profit-seeking over public health. Like all

Tomorrow at Walmart’s shareholders’ meeting in Bentonville, Arkansas, Walmart workers will call out America’s broken corporate governance system and propose that Walmart workers be included on its board of directors. Walmart associate Cat Davis will be joined by Senator Bernie Sanders (I-VT), who will speak on behalf of workers’ right to participate in corporate decision-making.

Economic inequality is on the rise. Corporate “shareholder primacy” means that the vast majority of today’s record corporate profits are used to increase the wealth of shareholders, through dividends and stock buybacks.[1] Meanwhile, real wages for non-executive workers have essentially remained stagnant for decades. Increasing worker bargaining power in the 21st century is necessary, and

The pharmaceutical industry isn’t working for most people in the US. Over 80 percent of Americans across the political spectrum believe that lowering drug costs should be a “top priority” for lawmakers and believe that prescription drug costs are “unreasonable.” This growing scrutiny presents an opportunity to question the ways that drug corporations run business, as

For nearly half of a century, America’s public corporations have been driven by a shareholder primacy approach to corporate governance, increasingly prioritizing shareholder payments over other, more productive uses of corporate resources. Over the same period, employee bargaining power has decreased and wages for nonexecutive workers have remained flat across sectors. In Ending Shareholder Primacy in Corporate Governance,